We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Sorafenib and azacitidine as salvage therapy for relapse of FLT3- ITD mutated AML after allo- SCT.
- Authors
Rautenberg, Christina; Nachtkamp, Kathrin; Dienst, Ariane; Schmidt, Pia Verena; Heyn, Claudia; Kondakci, Mustafa; Germing, Ulrich; Haas, Rainer; Kobbe, Guido; Schroeder, Thomas
- Abstract
Objective Patients with acute myeloid leukemia ( AML) carrying FLT3- ITD mutations ( FLT3- ITD+) who relapse after allogeneic transplantation (allo- SCT) have a very dismal prognosis with the currently available treatment options. Methods We treated eight patients with FLT3- ITD+ AML who had relapsed in median 91 d (range, 28-249) following allo- SCT with a combination of the multikinase inhibitor sorafenib and the DNA methyltransferase inhibitor azacitidine (Aza). Results Patients received a median of five cycles of Aza (range, 2-9) and sorafenib with a median daily dosage of 750 mg (range 400-800) for 129 d (range, 61-221). Six of eight patients received donor lymphocyte infusions ( DLI) with a median number of two DLI per patient (range, 1-4). Following this treatment, four patients (50%) achieved a complete remission and three of them a complete molecular remission. Median duration of CR was 182 d (range, 158-406), and two patients remain in ongoing remission for 406 and 168 d. Median overall survival was 322 d (range, 108-574 d) with three patients being currently alive. Conclusion Taken together, the combination of sorafenib, Aza, and DLI shows promising efficacy and deserves further evaluation in larger patient groups.
- Subjects
SORAFENIB; AZACITIDINE; SALVAGE therapy; ACUTE myeloid leukemia; DNA methyltransferases; THERAPEUTICS
- Publication
European Journal of Haematology, 2017, Vol 98, Issue 4, p348
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.12832